A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Irinotecan Liposome Injection in Patients With Advanced Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Irinotecan (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Adverse reactions
Sponsors CSPC Ouyi Pharmaceutical

26 Jul 2024 Status changed from recruiting to completed.
04 Jun 2024 Status changed from not yet recruiting to recruiting, according to results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
04 Jun 2024 Results (n=119; As of June 5th, 2023) assessing the safety and efficacy of breast cancer treated with HE072 in patients with highly pre-treated metastatic TNBC and HER2 negative breast cancer brain metastasis, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com